Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | UGT8 | Q16880 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29283185 | 0.84 | LMNA (0.41) | LMNAHRH3GPR119 | |
| SCHEMBL17749035 | 0.81 | SMN1; SMN2 (0.53) | HRH3SCN9ASMN1; SMN2 | |
| SCHEMBL31038214 | 0.79 | LMNA (0.65) | LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25194853 | 0.79 | LMNA (0.65) | LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20507602 | 0.78 | TRPV1 (0.49) | HRH3MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12639922 | 0.77 | LMNA (0.46) | LMNAMEN1KMT2ASMN1; SMN2OGA | |
| SCHEMBL17753925 | 0.76 | HRH4 (0.55) | MEN1KMT2AOGA | |
| SCHEMBL21434039 | 0.76 | SMO (0.53) | LMNA | |
| Hydrochloric Acid SCHEMBL19639695 | 0.75 | HRH4 (0.53) | MEN1KMT2AOGA | |
| SCHEMBL25197786 | 0.75 | LMNA (0.58) | LMNASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | LMNA 2473/4885HRH3 131/4885SCN9A 2658/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | LMNA 2473/4885HRH3 131/4885SCN9A 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.